Liposomal nanostructures for Gemcitabine and Paclitaxel delivery in pancreatic cancer.


Journal

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 02 06 2023
revised: 01 09 2023
accepted: 24 09 2023
medline: 6 11 2023
pubmed: 28 9 2023
entrez: 27 9 2023
Statut: ppublish

Résumé

Pancreatic cancer (PC) is an incurable disease with a high death rate in the world nowadays. Gemcitabine (GEM) and Paclitaxel (PTX) are considered as references of chemotherapeutic treatments and are commonly used in clinical applications. Factors related to the tumor microenvironment such as insufficient tumor penetration, toxicity, and drug resistance can limit the effectiveness of these therapeutic anticancer drugs. The use of different liposomal nanostructures is a way that can optimize the drug's effectiveness and reduce toxicity. Given the development of PC therapy, this review focuses on advances in Nano-formulation, characterization, and delivery systems of loaded GEM and PTX liposomes using chemotherapy, nucleic acid delivery, and stroma remodeling therapy. As a result, the review covers the literature dealing with the applications of liposomes in PC therapy.

Identifiants

pubmed: 37758121
pii: S0939-6411(23)00257-6
doi: 10.1016/j.ejpb.2023.09.014
pii:
doi:

Substances chimiques

Gemcitabine 0
Paclitaxel P88XT4IS4D
Liposomes 0
Deoxycytidine 0W860991D6

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

13-24

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Epiphane K Silli (EK)

School of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China. Electronic address: epiphanesilli@yahoo.com.

Mengfei Li (M)

School of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China. Electronic address: limengfei6535@163.com.

Yuting Shao (Y)

College of Engineering, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.

Yiran Zhang (Y)

College of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.

Guilin Hou (G)

College of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.

Jiaqian Du (J)

College of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.

Jingdan Liang (J)

College of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.

Ying Wang (Y)

School of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, China. Electronic address: ywang@cpu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH